ATE424208T1 - Proteinkinaseinhibitoren - Google Patents

Proteinkinaseinhibitoren

Info

Publication number
ATE424208T1
ATE424208T1 AT05744735T AT05744735T ATE424208T1 AT E424208 T1 ATE424208 T1 AT E424208T1 AT 05744735 T AT05744735 T AT 05744735T AT 05744735 T AT05744735 T AT 05744735T AT E424208 T1 ATE424208 T1 AT E424208T1
Authority
AT
Austria
Prior art keywords
angiogenesis
mammal
relates
compounds
protein kinase
Prior art date
Application number
AT05744735T
Other languages
English (en)
Inventor
Catherine Berset
Stephan Audetat
Julia Tietz
Tea Gunde
Alcide Barberis
Andreas Schumacher
Peter Traxler
Original Assignee
Oncalis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncalis Ag filed Critical Oncalis Ag
Application granted granted Critical
Publication of ATE424208T1 publication Critical patent/ATE424208T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05744735T 2004-06-09 2005-06-09 Proteinkinaseinhibitoren ATE424208T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04013572 2004-06-09

Publications (1)

Publication Number Publication Date
ATE424208T1 true ATE424208T1 (de) 2009-03-15

Family

ID=34968638

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05744735T ATE424208T1 (de) 2004-06-09 2005-06-09 Proteinkinaseinhibitoren

Country Status (8)

Country Link
US (1) US20070149535A1 (de)
EP (1) EP1765351B9 (de)
AT (1) ATE424208T1 (de)
AU (1) AU2005251408A1 (de)
CA (1) CA2570073A1 (de)
DE (1) DE602005013085D1 (de)
ES (1) ES2321315T3 (de)
WO (1) WO2005120513A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007147382A (ru) 2005-05-20 2009-06-27 Эррэй Биофарма Инк. (Us) Соединения, являющиеся ингибиторами raf, и способы их применения
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
DE602007006010D1 (de) 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
CA2654202A1 (en) * 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
PT2155747E (pt) * 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
WO2010083617A1 (en) * 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (de) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Hemmer des phosphodiesterase-10-enzyms
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
WO2022164934A1 (en) * 2021-01-26 2022-08-04 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Imidazo[1,2-a]pyrazine and imidazo[1,2-a]pyridine based tyrosyl-dna phosphodiesterase i (tdp1) inhibitors
US11970499B1 (en) 2023-12-22 2024-04-30 King Faisal University Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors
US12129257B1 (en) 2023-12-28 2024-10-29 King Faisal University Imidazo[1,2-a]pyrazine compounds as CK2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1218382E (pt) * 1999-10-08 2004-06-30 Gruenenthal Gmbh Derivados de imidazo-3-il-amina biciclica
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
DE10141212A1 (de) * 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CA2482991A1 (en) * 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof

Also Published As

Publication number Publication date
DE602005013085D1 (de) 2009-04-16
CA2570073A1 (en) 2005-12-22
EP1765351A1 (de) 2007-03-28
US20070149535A1 (en) 2007-06-28
ES2321315T3 (es) 2009-06-04
EP1765351B9 (de) 2010-03-24
EP1765351B1 (de) 2009-03-04
AU2005251408A1 (en) 2005-12-22
WO2005120513A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
DE602005013085D1 (de) Proteinkinaseinhibitoren
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
ATE554087T1 (de) Neue kinaseinhibitoren
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1765351

Country of ref document: EP

REN Ceased due to non-payment of the annual fee